Literature DB >> 28264846

Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.

Phillip J Bergen1, Jürgen B Bulitta2, Carl M J Kirkpatrick1, Kate E Rogers1,3, Megan J McGregor1, Steven C Wallis4, David L Paterson5, Roger L Nation3, Jeffrey Lipman4,6, Jason A Roberts4,6,7, Cornelia B Landersdorfer8,3,9.   

Abstract

Critically ill patients frequently have substantially altered pharmacokinetics compared to non-critically ill patients. We investigated the impact of pharmacokinetic alterations on bacterial killing and resistance for commonly used meropenem dosing regimens. A Pseudomonas aeruginosa isolate (MICmeropenem 0.25 mg/liter) was studied in the hollow-fiber infection model (inoculum ∼107.5 CFU/ml; 10 days). Pharmacokinetic profiles representing critically ill patients with augmented renal clearance (ARC), normal, or impaired renal function (creatinine clearances of 285, 120, or ∼10 ml/min, respectively) were generated for three meropenem regimens (2, 1, and 0.5 g administered as 8-hourly 30-min infusions), plus 1 g given 12 hourly with impaired renal function. The time course of total and less-susceptible populations and MICs were determined. Mechanism-based modeling (MBM) was performed using S-ADAPT. All dosing regimens across all renal functions produced similar initial bacterial killing (≤∼2.5 log10). For all regimens subjected to ARC, regrowth occurred after 7 h. For normal and impaired renal function, bacterial killing continued until 23 to 47 h; regrowth then occurred with 0.5- and 1-g regimens with normal renal function (fT>5×MIC = 56 and 69%, fCmin/MIC < 2); the emergence of less-susceptible populations (≥32-fold increases in MIC) accompanied all regrowth. Bacterial counts remained suppressed across 10 days with normal (2-g 8-hourly regimen) and impaired (all regimens) renal function (fT>5×MIC ≥ 82%, fCmin/MIC ≥ 2). The MBM successfully described bacterial killing and regrowth for all renal functions and regimens simultaneously. Optimized dosing regimens, including extended infusions and/or combinations, supported by MBM and Monte Carlo simulations, should be evaluated in the context of ARC to maximize bacterial killing and suppress resistance emergence.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  augmented renal clearance; critically ill; pharmacodynamic modeling; pharmacokinetics

Mesh:

Substances:

Year:  2017        PMID: 28264846      PMCID: PMC5404522          DOI: 10.1128/AAC.02642-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  62 in total

1.  High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.

Authors:  Justin R Lenhard; Jürgen B Bulitta; Terry D Connell; Natalie King-Lyons; Cornelia B Landersdorfer; Soon-Ee Cheah; Visanu Thamlikitkul; Beom Soo Shin; Gauri Rao; Patricia N Holden; Thomas J Walsh; Alan Forrest; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  J Antimicrob Chemother       Date:  2016-09-15       Impact factor: 5.790

2.  Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Amy N Schilling; Shadi Neshat; Keith Poole; David A Melnick; Elizabeth A Coyle
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

3.  Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion.

Authors:  J W Mouton; A A Vinks; N C Punt
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

Review 4.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.

Authors:  J W Mouton; J G den Hollander
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

6.  Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model.

Authors:  Xin Li; Lin Wang; Xian-Jia Zhang; Yang Yang; Wei-Tao Gong; Bin Xu; Ying-Qun Zhu; Wei Liu
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

Review 7.  Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients.

Authors:  Jurgen B Bulitta; Cornelia B Landersdorfer; Alan Forrest; Silvia V Brown; Michael N Neely; Brian T Tsuji; Arnold Louie
Journal:  Curr Pharm Biotechnol       Date:  2011-12       Impact factor: 2.837

8.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.

Authors:  M H Kollef; G Sherman; S Ward; V J Fraser
Journal:  Chest       Date:  1999-02       Impact factor: 9.410

Review 9.  Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Authors:  Philip D Lister; Daniel J Wolter; Nancy D Hanson
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

10.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?

Authors:  Jason A Roberts; Sanjoy K Paul; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman
Journal:  Clin Infect Dis       Date:  2014-01-14       Impact factor: 9.079

View more
  13 in total

Review 1.  Prolonged Versus Intermittent Infusion of β-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models.

Authors:  Sofie Dhaese; Aaron Heffernan; David Liu; Mohd Hafiz Abdul-Aziz; Veronique Stove; Vincent H Tam; Jeffrey Lipman; Jason A Roberts; Jan J De Waele
Journal:  Clin Pharmacokinet       Date:  2020-10       Impact factor: 6.447

Review 2.  What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.

Authors:  Chandra Datta Sumi; Aaron J Heffernan; Jeffrey Lipman; Jason A Roberts; Fekade B Sime
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

3.  Personalized antibiotic dosing for the critically ill.

Authors:  Jason A Roberts; Claire Roger; Jan J De Waele
Journal:  Intensive Care Med       Date:  2019-01-14       Impact factor: 17.440

4.  Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.

Authors:  Cornelia B Landersdorfer; Vanessa E Rees; Rajbharan Yadav; Kate E Rogers; Tae Hwan Kim; Phillip J Bergen; Soon-Ee Cheah; John D Boyce; Anton Y Peleg; Antonio Oliver; Beom Soo Shin; Roger L Nation; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

5.  Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.

Authors:  Rajbharan Yadav; Phillip J Bergen; Kate E Rogers; Carl M J Kirkpatrick; Steven C Wallis; Yuling Huang; Jürgen B Bulitta; David L Paterson; Jeffrey Lipman; Roger L Nation; Jason A Roberts; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

6.  Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.

Authors:  Rajbharan Yadav; Kate E Rogers; Phillip J Bergen; Jürgen B Bulitta; Carl M J Kirkpatrick; Steven C Wallis; David L Paterson; Roger L Nation; Jeffrey Lipman; Jason A Roberts; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

Review 7.  Rationalizing antimicrobial therapy in the ICU: a narrative review.

Authors:  Jean-François Timsit; Matteo Bassetti; Olaf Cremer; George Daikos; Jan de Waele; Andre Kallil; Eric Kipnis; Marin Kollef; Kevin Laupland; Jose-Artur Paiva; Jesús Rodríguez-Baño; Étienne Ruppé; Jorge Salluh; Fabio Silvio Taccone; Emmanuel Weiss; François Barbier
Journal:  Intensive Care Med       Date:  2019-01-18       Impact factor: 17.440

8.  Augmented Renal Clearance in Critically Ill Patients: A Systematic Review.

Authors:  Idoia Bilbao-Meseguer; Alicia Rodríguez-Gascón; Helena Barrasa; Arantxazu Isla; María Ángeles Solinís
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

9.  Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.

Authors:  Vanessa E Rees; Rajbharan Yadav; Kate E Rogers; Jürgen B Bulitta; Veronika Wirth; Antonio Oliver; John D Boyce; Anton Y Peleg; Roger L Nation; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

10.  Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial.

Authors:  Adela Benítez-Cano; Sonia Luque; Luisa Sorlí; Jesús Carazo; Isabel Ramos; Nuria Campillo; Víctor Curull; Albert Sánchez-Font; Carles Vilaplana; Juan P Horcajada; Ramón Adalia; Silvia Bermejo; Enric Samsó; William Hope; Santiago Grau
Journal:  Crit Care       Date:  2020-02-17       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.